medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2022, Number 3

<< Back Next >>

An Med Asoc Med Hosp ABC 2022; 67 (3)

Reasons for the resistance to the application of the vaccine against COVID-19 in the city of Mexicali, Baja California

Medina RCR, Palmer MLY, Palmer MS, Bueno ÁÁ, Cuenca VAN, Herrera QG, Mascareño FA

Language: Spanish
References: 16
Page: 190-194
PDF size: 254.99 Kb.


ABSTRACT

Introduction: at the end of 2019, when the first case of COVID-19 (Coronavirus disease 2019) was presented, various measures were carried out to contain the contagion. The uncertainty surrounding vaccination caused a group of people to refuse to be vaccinated. Objective: to know the reasons for resistance to vaccination against COVID-19 in Mexicali, Baja California. Material and methods: Descriptive, cross-sectional study, an online survey was conducted, with a non-probabilistic sample at convenience, for 4 weeks. Inclusion criteria, people over 18 years of age who wish to participate. Statistical analysis, measures of central tendency and dispersion. Frequencies and percentages, for comparison of groups χ2 and t of Student. Results: 712 participants were studied, with an average age of 35.5 ± 1. In the unvaccinated group, their frequency was 85 (11.9%). The age was higher in the unvaccinated group, the male sex was 50 (58.8%) p = 0.000; the major degree of studies was university and the main reason for non-vaccination was that the vaccines were developed very quickly and are not safe. Conclusion: In the group of unvaccinated the male sex predominated, with a higher age in the unvaccinated, the highest level of studies was university and the main reason for not vaccinating is that vaccines have been developed very quickly and are not safe.


REFERENCES

  1. Escudero X, Guarner J, Galindo-Fraga A, Escudero-Salamanca M, Alcocer-Gamba MA, Del Rio C. La pandemia de Coronavirus SARS-CoV-2 (COVID-19): situación actual e implicaciones para México. Arch Cardiol Mex. 2020; 90 (Supl): 7-14.

  2. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KR, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021; 21 (2): e26-e35.

  3. WHO. Weekly epidemiological update on COVID-19. [Consulted 1 February 2022]. Available in: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-february-2022

  4. Gras-Valenti P, Chico-Sánchez P, Algado-Sellés N, Jiménez-Sepúlveda NJ, Gómez-Sotero IL, Fuster-Pérez M et al. Efectividad de la primera dosis de vacuna BNT162b2 para prevenir la COVID-19 en personal sanitario. Rev Esp Salud Pública. 2021; 95 (1): e1-e12.

  5. Hajj Hussein I, Chams N, Chams S, El Sayegh S, Badran R, Raad M et al. Vaccines trough centuries: major cornerstones of global health. Front Public Health. 2015; 3: 269.

  6. Bonilla N, Simancas-Racines D, Montesinos-Guevara C. Vacunas para Covid-19: seguridad, elaboración y distribución. PFR. 2021; 6 (2).

  7. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397 (10269): 99-111.

  8. Kimberly A, Fisher MD, Bloomstone SJ, Walder J, Crawford S, Fousyzi H et al. Attitudes toward a potential SARS-CoV-2 Vaccine: A survey of U.S. adults. Ann Intern Med. 2020; 173 (12): 964-973. doi: 10.7326/M20-3569.

  9. Castillo-Santana E, de-Jesús-Aramboles Y, Catoia-Varela M, Bautista-Barragan CE, Lara-Reyes E, Días-da-Costa M. Barreras para la inmunización en República Dominicana y COVID-19. Vacci Monitor. 2021; 30 (3): 96-104.

  10. MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine; 2015; 33: 4161-4164.

  11. Mertens G, Gerritsen L, Duijndam S, Salemink E, Engelhard IM. Fear of the coronavirus (COVID-19): predictors in an online study conducted in March 2020. J Anxiety Disor. 2020; 74: 102258.

  12. Secretaría de salud. Informe técnico COVID-19. México: SSA; 2021. Informe técnico diario (consultado el 20 de febrero 2022). Disponible en: Comunicado_Tecnico_Diario_COVID- 19_2021.08.04.pdf (www.gob.mx)

  13. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor K. Attitudes toward a potential SARS-CoV-2 Vaccine: a survey of U.S. adults. Ann Intern Med. 2020; 173 (12): 964-973.

  14. Malik AA, McFadden SM, Elharake J, Omer SB. Determinants of COVID-19 vaccine acceptance in the US. EClinical Medicine. 2020; 26:100495.

  15. COSMO-SPAIN. (Consultado 20 enero 2022) Disponible en: https://portalcne.isciii,es/cosmo-spain/

  16. Rodrigues CMC, Plotkin SA. Impact of vaccines; health, economic and social perspectives. Front Microbiol. 2020; 11: 15.



EVIDENCE LEVEL

IV




2020     |     www.medigraphic.com